Current Clinical Trials

Multicenter Phase II , Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (PISCES)

OBJECTIVES: Evaluate the efficacy of the combination of KEYTRUDA® and ImmunoPulse® IL-12 in advanced metastatic melanoma patients that are progressing on pembrolizumab or nivolumab.

STATUS: Recruiting Learn More

Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer

OBJECTIVES: Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer


STATUS: Recruiting Learn More

Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation

OBJECTIVES: Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma †

†This is a collaboration with University of California, San Francisco


STATUS: Not Recruiting Learn More
Real Time Web Analytics